Naing Lin Shan
Overview
Explore the profile of Naing Lin Shan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
118
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Shan N, Gould B, Wang X, Bonora G, Blenman K, Foldi J, et al.
J Liq Biopsy
. 2025 Mar;
6:100168.
PMID: 40027305
Purpose: Pathologic response after preoperative/neoadjuvant chemotherapy (NAC) is a continuum that can range from complete pathologic response (pCR) to extensive residual disease (RD). We hypothesized that post-NAC plasma circulating tumor...
2.
Gunasekharan V, Lin H, Marczyk M, Rios-Hoyo A, Campos G, Shan N, et al.
Breast Cancer Res Treat
. 2024 Aug;
208(3):657-671.
PMID: 39177932
Purpose: Metabolic rewiring in malignant transformation is often accompanied by altered expression of metabolic isozymes. Phosphoenolpyruvate carboxykinase-2 (PCK2) catalyzes the rate-limiting step of gluconeogenesis and is the dominant isoform in...
3.
Rios-Hoyo A, Shan N, Li A, Pearson A, Pusztai L, Howard F
Front Med (Lausanne)
. 2024 Jul;
11:1380148.
PMID: 38966538
Background: The use of large language models (LLM) has recently gained popularity in diverse areas, including answering questions posted by patients as well as medical professionals. Objective: To evaluate the...
4.
Qing T, Karn T, Rozenblit M, Foldi J, Marczyk M, Shan N, et al.
NPJ Breast Cancer
. 2022 Nov;
8(1):119.
PMID: 36344517
The RxPONDER and TAILORx trials demonstrated benefit from adjuvant chemotherapy in patients age ≤ 50 with node-positive breast cancer and Recurrence Score (RS) 0-26, and in node-negative disease with RS...
5.
Shan N, Kahn A, Pusztai L
Br J Cancer
. 2022 Oct;
128(3):459-460.
PMID: 36216884
Recent technological advances uncovered intricate biological processes underlying intratumor heterogeneity with clinical implications. These insights led to novel biomarkers for immunotherapies, justified serial tumour biopsies for therapeutic target profiling, inspired...
6.
Marczyk M, Gunasekharan V, Casadevall D, Qing T, Foldi J, Sehgal R, et al.
Cancer Res
. 2022 Mar;
82(9):1698-1711.
PMID: 35247885
Significance: This study exploits the loss of metabolic isozyme diversity common in cancer and reveals a rich pool of potential therapeutic targets that will allow the repurposing of existing inhibitors...
7.
Shan N, Minden A, Furmanski P, Bak M, Cai L, Wernyj R, et al.
Cancer Prev Res (Phila)
. 2020 May;
13(8):673-686.
PMID: 32467291
Ductal carcinoma (DCIS), which accounts for one out of every five new breast cancer diagnoses, will progress to potentially lethal invasive ductal carcinoma (IDC) in about 50% of cases. Vitamin...
8.
Cordover E, Wei J, Patel C, Shan N, Gionco J, Sargsyan D, et al.
Chem Res Toxicol
. 2019 Dec;
33(2):482-491.
PMID: 31876149
Triple negative breast cancer (TNBC) is difficult to treat due to lack of druggable targets. We have found that treatment with the small molecule inhibitor KPT-9274 inhibits growth of TNBC...
9.
Shin S, Jeong B, Wall B, Li J, Shan N, Wen Y, et al.
Oncogenesis
. 2018 Nov;
7(11):86.
PMID: 30425240
Our research group demonstrated that riluzole, an inhibitor of glutamatergic signaling reduced melanoma cell proliferation in vitro and tumor progression in vivo. The underlying mechanisms of riluzole are largely unknown....
10.
Bak M, Furmanski P, Shan N, Lee H, Bao C, Lin Y, et al.
Carcinogenesis
. 2018 May;
39(8):1045-1055.
PMID: 29846560
Estrogen plays an important role in breast cancer development. While the mechanism of the estrogen effects is not fully elucidated, one possible route is by increasing the stem cell-like properties...